Compare Strategy Inc. (MSTR) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs Novavax Inc — how do they compare? Strategy Inc. trades at $154.81 (market cap $60.40B), while Novavax Inc trades at $12.69 (market cap $1.82B). The key difference: Strategy Inc. is far larger — about 33.2× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Strategy Inc. for 112 Days and Novavax Inc for 59 Days on average.
| MSTR | NVAX | |
|---|---|---|
Market Cap | $60.40B | $1.82B |
Volume | 23,421,830 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $320.29 | $12.56 |
52-Week Low | $82.31 | $6.22 |
Typical Hold Time | 112 Days | 59 Days |
Enterprise Value | $79.16B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR stock trades at $154.34, up 0.63% with a bullish technical signal and strong analyst support. The company shows concerning fundamentals with negative net income margins of -6,102.96% and three consecutive earnings misses, though revenue remains stable around $477 million. Recent news highlights Citigroup's upgraded price target to $240 and the stock's 35% monthly surge, positioning it as a high-risk, high-reward play tied to Bitcoin market movements despite operational challenges.
Outlook remains polarized: 62% analyst buy ratings and a $253 consensus target suggest 64% upside, but extreme profitability risks and volatile cash flows demand caution. Investment opportunity hinges on Bitcoin's performance amplifying equity value, while risks include persistent losses, debt burden, and sensitivity to crypto market swings.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
